- Home
- GECC vs CLNN Comparison
GECC vs CLNN Comparison
Compare GECC & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | CLNN |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 120.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GECC | CLNN |
|---|---|---|
| Price | $7.01 | $6.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $10.75 | ★ $32.67 |
| AVG Volume (30 Days) | 91.2K | ★ 318.3K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 19.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,553,000.00 | $214,000.00 |
| Revenue This Year | $32.16 | N/A |
| Revenue Next Year | $3.26 | $87.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.68 | N/A |
| 52 Week Low | $7.18 | $2.28 |
| 52 Week High | $11.46 | $13.50 |
Technical Indicators
Market Signals| Indicator | GECC | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 38.60 |
| Support Level | $7.57 | $5.42 |
| Resistance Level | $7.95 | $7.03 |
| Average True Range (ATR) | 0.22 | 0.98 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 1.47 | 18.82 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.